Tags

Type your tag names separated by a space and hit enter

Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
J Infect Dis. 2004 Jul 01; 190(1):83-90.JI

Abstract

BACKGROUND

Shifts in peak measles incidence to children <12 months old and the associated high mortality support the study of an early 2-dose measles vaccine regimen.

METHODS

Fifty-five infants were vaccinated with measles vaccine at age 6 (n=32) or 9 (n=23) months, followed by measles-mumps-rubella (MMR)-II vaccine at age 12 months. A control group received MMR-II only at age 12 months. Measles-specific humoral and cell-mediated immunity were evaluated before, 12 weeks after measles immunization, and 24 weeks after MMR-II.

RESULTS

Measles-specific T cell proliferation after both doses of vaccine was equivalent, regardless of age or the presence of passive antibodies. Seroconversion rates, geometric mean titers, and the percentage of infants with antibody titers >120 mIU after the first measles vaccine were lower in infants vaccinated at age 6 months, regardless of the presence of passive antibodies, but measles humoral responses increased after the administration of MMR-II vaccine in children initially vaccinated at age 6 or 9 months.

CONCLUSION

Measles vaccination elicits T cell responses in infants as young as 6 months old, which may prime the humoral response to the second dose. Initiating measles vaccination as an early 2-dose regimen results in an immunologic response that is likely to have clinical benefits in developed and developing countries.

Authors+Show Affiliations

Department of Pediatrics, Stanford University School of Medicine, Stanford, California 94305-5208, USA. hagans@stanford.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15195246

Citation

Gans, Hayley A., et al. "Humoral and Cell-mediated Immune Responses to an Early 2-dose Measles Vaccination Regimen in the United States." The Journal of Infectious Diseases, vol. 190, no. 1, 2004, pp. 83-90.
Gans HA, Yasukawa LL, Alderson A, et al. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis. 2004;190(1):83-90.
Gans, H. A., Yasukawa, L. L., Alderson, A., Rinki, M., DeHovitz, R., Beeler, J., Audet, S., Maldonado, Y., & Arvin, A. M. (2004). Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. The Journal of Infectious Diseases, 190(1), 83-90.
Gans HA, et al. Humoral and Cell-mediated Immune Responses to an Early 2-dose Measles Vaccination Regimen in the United States. J Infect Dis. 2004 Jul 1;190(1):83-90. PubMed PMID: 15195246.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. AU - Gans,Hayley A, AU - Yasukawa,Linda L, AU - Alderson,Amanda, AU - Rinki,Mary, AU - DeHovitz,Ross, AU - Beeler,Judith, AU - Audet,Susette, AU - Maldonado,Yvonne, AU - Arvin,Ann M, Y1 - 2004/05/26/ PY - 2003/09/16/received PY - 2003/12/04/accepted PY - 2004/6/15/pubmed PY - 2004/8/4/medline PY - 2004/6/15/entrez SP - 83 EP - 90 JF - The Journal of infectious diseases JO - J Infect Dis VL - 190 IS - 1 N2 - BACKGROUND: Shifts in peak measles incidence to children <12 months old and the associated high mortality support the study of an early 2-dose measles vaccine regimen. METHODS: Fifty-five infants were vaccinated with measles vaccine at age 6 (n=32) or 9 (n=23) months, followed by measles-mumps-rubella (MMR)-II vaccine at age 12 months. A control group received MMR-II only at age 12 months. Measles-specific humoral and cell-mediated immunity were evaluated before, 12 weeks after measles immunization, and 24 weeks after MMR-II. RESULTS: Measles-specific T cell proliferation after both doses of vaccine was equivalent, regardless of age or the presence of passive antibodies. Seroconversion rates, geometric mean titers, and the percentage of infants with antibody titers >120 mIU after the first measles vaccine were lower in infants vaccinated at age 6 months, regardless of the presence of passive antibodies, but measles humoral responses increased after the administration of MMR-II vaccine in children initially vaccinated at age 6 or 9 months. CONCLUSION: Measles vaccination elicits T cell responses in infants as young as 6 months old, which may prime the humoral response to the second dose. Initiating measles vaccination as an early 2-dose regimen results in an immunologic response that is likely to have clinical benefits in developed and developing countries. SN - 0022-1899 UR - https://www.unboundmedicine.com/medline/citation/15195246/Humoral_and_cell_mediated_immune_responses_to_an_early_2_dose_measles_vaccination_regimen_in_the_United_States_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1086/421032 DB - PRIME DP - Unbound Medicine ER -